Sat Aug 1 01:23:20 SGT 2015  
    Botox® cost, Singapore (SG)

Botox® cost, Singapore (SG)


Botox® cost, Singapore (SG) @singaporebotox_com: Botox® Cosmetic, Dysport®, BTX-A, botulinum toxin type A injection, wrinkle removal treatment clinic, Singapore. Cost/price for treating glabella frown lines, crow's feet, and horizontal forehead lines. Definitions, references, and latest news.


Botox® price. Average Botox® cost.

AreaIU/spotSpotsTotal IUPrice @ SG$15/IU
Horizontal forehead lines2816SG$240
Glabellar frown lines4520SG$300
Crow's feet4624SG$360

Jaw slimming / face slimming / Botox® jaw reduction / Botox® jaw slimming / Botox® face slimming price.

AreaIU/spotSpotsTotal IUPrice @ SG$15/IU
Jaw reduction8 to 12656SG$840

Botox® treatment is with the original Allergan Botox® Cosmetic

  • The units differ for different brands.
  • Price quoted is for average ladies face, with average musculature.
  • Muscular men might require up to twice as much.
  • Minimum charge is for 10 units.

Botox® is one of the trade names for botulinum toxin, which is a protein produced by the bacterium clostridium botulinum.

Aesthetic services available:

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Botox® cost, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.


Latest News

Effect of Botulinum Toxin Type A on Differentiation of Fibroblasts Derived from Scar Tissue
Fri, 31 Jul 2015 09:16:17 +0100 | Plastic and Reconstructive Surgery
Conclusion: The authors’ results show that botulinum toxin type A directly inhibits fibroblast-to-myofibroblast differentiation in vitro, and indicate its potential for use in treating wounds expected to develop into hypertrophic scars after trauma, burn, or surgery.

Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides
Sun, 26 Jul 2015 12:00:00 +0100 | Healthcare News
Allergan,the drug giant that is famed for Botox but also makes antibiotics and an Alzheimer's treatment, will spend $560 million to purchase Naurex, an Evanston, Ill.-based developer of antidepressants that can work in hours, compared to weeks for existing depression pills. The drug giant says it sees opportunity in a depression drug that works in a new way, and hopes Naurex's experimental medicines might someday be shown to prevent suicidal people from killing themselves. (Source: Healthcare News)

Allergan said to be exploring split into two businesses: source
Sat, 25 Jul 2015 03:03:56 +0100 | Reuters: Health
(Reuters) - Allergan Plc is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday, potentially adding the botox-maker to a list of large drugmakers realigning themselves to focus on specific areas of their businesses. (Source: Reuters: Health)

eComment. Alternative approaches to pyloric disruption after oesophagectomy: Stapled pyloroplasty versus dilatation and botox injection
Wed, 22 Jul 2015 00:00:00 +0100 | Interactive CardioVascular and Thoracic Surgery
(Source: Interactive CardioVascular and Thoracic Surgery)

Effect of botulinum toxin type A in the contraction of lesions treated with full-thickness grafts
Tue, 21 Jul 2015 00:00:00 +0100 | European Journal of Plastic Surgery

Efficacy and Safety of NABOTA in Post-stroke Upper Limb Spasticity: A phase 3 multicenter, double-blinded, randomized controlled trial
Tue, 21 Jul 2015 00:00:00 +0100 | Journal of the Neurological Sciences
Botulinum toxin A is widely used in the clinics to reduce spasticity and improve upper limb function for post-stroke patients. Efficacy and safety of a new botulinum toxin type A, NABOTA (DWP450) in post-stroke upper limb spasticity was evaluated in comparison with Botox (Onabotulinum toxin A). A total of 197 patients with post-stroke upper limb spasticity were included in this study and randomly assigned to NABOTA group (n=99) or Botox group (n=98). Wrist flexors with modified Ashworth Scale (MAS) grade 2 or greater, and elbow flexors, thumb flexors and finger flexors with MAS 1 or greater were injected with either drug. (Source: Journal of the Neurological Sciences)

Men need to wear baggy trousers if they are trying for babies
Sun, 19 Jul 2015 18:30:10 +0100 | The Telegraph : Health Advice
Doctor's Diary: As Rod Stewart has found out, tight trousers are bad for fertility and a simple change of outfit may do the trick (Source: The Telegraph : Health Advice)

Myasthenia gravis exacerbation with low dose ocular botulinum toxin for epiphoria
Fri, 17 Jul 2015 00:00:00 +0100 | Journal of Clinical Neuroscience
We present a man with clinically stable systemic myasthenia gravis (MG) which flared with a low dose of peripherally injected botulinum toxin type A (BTX-A). Botulinum toxin drugs generally have an excellent safety profile, however, they are contentious in patients with neuromuscular disorders. Despite this, there remain limited reports on the systemic effects of botulinum therapy in patients with MG. This man is one of less than 10 reported patients worldwide in whom MG was exacerbated by a peripheral BTX-A injection. This is an important reminder to Australian clinicians of the potential risks of this common place medication in patients with neuromuscular disorders, even those with stable disease. (Source: Journal of Clinical Neuroscience)

Knee flexion contracture treated with botulinum toxin type A in patients with haemophilia (PWH)
Fri, 17 Jul 2015 00:00:00 +0100 | Haemophilia
ConclusionsTreatment of KFC with BTX‐A improves knee‐related functional activities, with the advantage of being a low‐cost procedure and easy to apply. (Source: Haemophilia)

Valeant Pharma to acquire contact maker Unilens for $28m
Mon, 13 Jul 2015 18:11:58 +0100 | Mass Device
Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) said today it entered into an agreement to acquire Unilens Vision for $28 million, including $5 million in debt.